How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis?
نویسندگان
چکیده
منابع مشابه
How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis?
Before the recent approvement of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration (AMD), bevazicumab (Avastin) had been successfully used as an off-label treatment for this condition. As a consequence, in daily practice we are confronted with a large number of patients having received Avastin injections in the past, now facing a recurrence of the disease ...
متن کاملIntravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization
We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...
متن کاملSwitch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
BACKGROUND To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS Observational clinical study was performed. We measured the structural outcome (CMT on SD-OCT; μm) and the visual outcome (best correct...
متن کاملFeasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration.
PURPOSE To assess the feasibility and potential obstacles of a departmental switch from ranibizumab (Lucentis, Genentech, South San Francisco, CA) to bevacizumab (Avastin, Genentech) for the treatment of neovascular age-related macular degeneration (AMD). METHODS A total of 154 eyes treated for wet AMD with ranibizumab or bevacizumab were examined over a 10-month period. The treatment protoco...
متن کاملIntracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye
Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Ophthalmology
سال: 2008
ISSN: 0007-1161
DOI: 10.1136/bjo.2008.138396